Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Substances Generally Recognized as Safe: Notification Procedure, 29216-29217 [2019-13220]
Download as PDF
29216
Federal Register / Vol. 84, No. 120 / Friday, June 21, 2019 / Notices
TABLE 3—STUDY 2 DESIGN: HEMATOLOGY
Indication presentation
Material information in
superimposed text only
Material information in audio only
Material information in
superimposed text + audio
Material information not in superimposed text or audio
(Control)
Audio: Drug Y is used to treat multiple myeloma.
Superimposed text: Drug Y is used
to treat multiple myeloma in
combination with dexamethasone, in people who have received at least three prior medicines to treat multiple myeloma.
Audio: Drug Y is used to treat
multiple myeloma in combination with dexamethasone, in
people who have received at
least three prior medicines to
treat multiple myeloma.
Superimposed text: Drug Y is
used to treat multiple myeloma.
Audio: Drug Y is used to treat
multiple myeloma in combination with dexamethasone, in
people who have received at
least three prior medicines to
treat multiple myeloma.
Superimposed text: Drug Y is
used to treat multiple myeloma
in combination with dexamethasone, in people who have received at least three prior medicines to treat multiple myeloma.
Audio: Drug Y is used to treat
multiple myeloma.
Superimposed text: Drug Y is
used to treat multiple myeloma.
Note. Study 2 will use the overall survival ad from Study 1.
FDA estimates the burden of this
collection of information as follows:
TABLE 4—ESTIMATED ANNUAL REPORTING BURDEN 1
Number of
respondents
Activity
Total
annual
responses
Average burden per
response
Total
hours
Cognitive Interview screener ................................
Cognitive Interviews ..............................................
Pretests 1 and 2 screener ....................................
Pretests 1 and 2 ...................................................
Study 1 screener ..................................................
Study 1 ..................................................................
Study 2 screener ..................................................
Study 2 ..................................................................
30
18
200
120
1,167
700
867
520
1
1
1
1
1
1
1
1
30
18
200
120
1,167
700
867
520
0.08 (5 minutes) ...........
1 (60 minutes) ..............
0.08 (5 minutes) ...........
0.33 (20 minutes) .........
0.08 (5 minutes) ...........
0.33 (20 minutes) .........
0.08 (5 minutes) ...........
0.33 (20 minutes) .........
2.4
18
16
39.6
93.36
231
69.36
171.6
Total ...............................................................
........................
........................
........................
.......................................
641.32
1
There are no capital costs or operating and maintenance costs associated with this collection of information.
II. References
The following references are on
display with the Dockets Management
Staff (see ADDRESSES) and are available
for viewing by interested persons
between 9 a.m. and 4 p.m., Monday
through Friday; these are not available
electronically at https://
www.regulations.gov as these references
are copyright protected. Some may be
available at the website address, if
listed. FDA has verified the website
addresses, as of the date this document
publishes in the Federal Register, but
websites are subject to change over time.
jspears on DSK30JT082PROD with NOTICES
Number of
responses per
respondent
for Consumer Reporting of Side Effects
in Direct-to-Consumer Television
Advertisements.’’ Journal of Public
Policy & Marketing, 35(1):108–123, 2016.
3. Sullivan, H.W., V. Boudewyns, A.C.
O’Donoghue, et al., ‘‘Attention to and
Distraction from Risk Information in
Prescription Drug Advertising: An EyeTracking Study.’’ Journal of Public Policy
& Marketing, 36(2):236–245, 2017.
Dated: June 14, 2019.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
18:30 Jun 20, 2019
Jkt 247001
Food and Drug Administration
[Docket No. FDA–2012–N–0021]
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Substances
Generally Recognized as Safe:
Notification Procedure
AGENCY:
[FR Doc. 2019–13128 Filed 6–20–19; 8:45 am]
HHS.
BILLING CODE 4164–01–P
ACTION:
1. Kim, J., J. Gao, L. Amiri-Kordestani, et al.,
‘‘Patient-Friendly Language to Facilitate
Treatment Choice for Patients with
Cancer.’’ The Oncologist, 10.1634/
theoncologist.2018-0761, 2019. Available
from: https://
theoncologist.alphamedpress.org/
content/early/2019/05/16/
theoncologist.2018-0761.short?rss=1.
2. Aikin, K.J., A.C. O’Donoghue, C.M. Squire,
et al., ‘‘An Empirical Examination of the
FDAAA-Mandated Toll-Free Statement
VerDate Sep<11>2014
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
PO 00000
Food and Drug Administration,
Notice.
The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
DATES: Fax written comments on the
collection of information by July 22,
2019.
SUMMARY:
Frm 00060
Fmt 4703
Sfmt 4703
E:\FR\FM\21JNN1.SGM
21JNN1
29217
Federal Register / Vol. 84, No. 120 / Friday, June 21, 2019 / Notices
To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, Fax: 202–
395–7285, or emailed to oira_
submission@omb.eop.gov. All
comments should be identified with the
OMB control number 0910–0342. Also
include the FDA docket number found
in brackets in the heading of this
document.
ADDRESSES:
FOR FURTHER INFORMATION CONTACT:
Domini Bean, Office of Operations,
Food and Drug Administration, Three
White Flint North, 10A–12M, 11601
Landsdown St., North Bethesda, MD
20852, 301–796–5733, PRAStaff@
fda.hhs.gov.
In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
collection of information to OMB for
review and clearance.
SUPPLEMENTARY INFORMATION:
Substances Generally Recognized as
Safe (GRAS): Notification Procedure—
21 CFR Part 170, Subpart E and 21 CFR
Part 570, Subpart E
OMB Control Number 0910–0342—
Extension
The Federal Food, Drug, and Cosmetic
Act (FD&C Act) requires that all food
additives (as defined by section 201(s)
(21 U.S.C. 321(s)) be approved by FDA
before they are marketed. Section 409 of
the FD&C Act (21 U.S.C. 349)
establishes a premarket approval
requirement for ‘‘food additives.’’
Section 201(s) of the FD&C Act provides
an exclusion to the definition of food
additive and thus from the premarket
approval requirement, for uses of
substances that are GRAS by qualified
experts. The GRAS provision of section
201(s) of the FD&C Act is implemented
in (part 170) 21 CFR part 170 and (part
570) 21 CFR part 570 for human food
and animal food, respectively. Part 170,
subpart E and part 570, subpart E
provide a standard format for the
submission of a notice. This collection
utilizes a voluntary administrative
procedure for notifying FDA about a
conclusion that a substance is GRAS
under the conditions of its intended use
in human food or animal food. The
information submitted to us in a GRAS
notice is necessary to allow us to
administer efficiently the FD&C Act’s
various provisions that apply to the use
of substances added to food, specifically
with regard to whether a substance is
GRAS under the conditions of its
intended use or is a food additive
subject to premarket review. We use the
information collected through the GRAS
notification procedures to complete our
evaluation within specific timelines.
Description of Respondents: The
respondents to this collection of
information are manufacturers of
substances used in human food and
animal food and feed.
In the Federal Register of March 12,
2019 (84 FR 8876), we published a 60day notice requesting public comment
on the proposed collection of
information. No comments were
received. We estimate the burden of the
information collection as follows:
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
Number of
respondents
Activity; 21 CFR section
GRAS notification procedure for human food; 170.210–
170.280 (part 170, subpart E) ..........................................
GRAS notification procedure for animal food and animal
feed; 570.210–570.280 (part 570, subpart E) ..................
Total ..............................................................................
1 There
Number of
responses per
respondent
Average
burden per
response
Total hours
100
1
100
170
17,000
25
1
25
170
4,250
........................
........................
75
........................
21,250
are no capital costs or operating and maintenance costs associated with this collection of information.
Our estimated burden reflects an
overall increase of 8,500 hours, which
corresponds to an increase in GRAS
submissions for human food from 50 to
100 we have received over the last 2
years.
Dated: June 17, 2019.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2019–13220 Filed 6–20–19; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Health Resources and Services
Administration (HRSA), Department of
Health and Human Services.
ACTION: Notice.
FOR FURTHER INFORMATION CONTACT:
In compliance with the
requirement for opportunity for public
comment on proposed data collection
projects of the Paperwork Reduction Act
of 1995, HRSA announces plans to
submit an Information Collection
Request (ICR), described below, to the
Office of Management and Budget
18:30 Jun 20, 2019
Jkt 247001
Comments on this Information
Collection Request must be received no
later than August 20, 2019.
DATES:
ADDRESSES:
SUMMARY:
VerDate Sep<11>2014
(OMB). Prior to submitting the ICR to
OMB, HRSA seeks comments from the
public regarding the burden estimate,
below, or any other aspect of the ICR.
Agency Information Collection
Activities: Proposed Collection: Public
Comment Request Information
Collection Request Title: Small Rural
Hospital Transition Project (SRHT),
OMB No. 0906–0026—Extension
AGENCY:
jspears on DSK30JT082PROD with NOTICES
Total annual
responses
PO 00000
Frm 00061
Fmt 4703
Sfmt 4703
Submit your comments to
paperwork@hrsa.gov or mail the HRSA
Information Collection Clearance
Officer, Room 14N136B, 5600 Fishers
Lane, Rockville, Maryland 20857.
To
request more information on the
proposed project or to obtain a copy of
the data collection plans and draft
instruments, email paperwork@hrsa.gov
or call Lisa Wright-Solomon, the HRSA
Information Collection Clearance Officer
at (301) 443–1984.
When
submitting comments or requesting
information, please include the
SUPPLEMENTARY INFORMATION:
E:\FR\FM\21JNN1.SGM
21JNN1
Agencies
[Federal Register Volume 84, Number 120 (Friday, June 21, 2019)]
[Notices]
[Pages 29216-29217]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-13220]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2012-N-0021]
Agency Information Collection Activities; Submission for Office
of Management and Budget Review; Comment Request; Substances Generally
Recognized as Safe: Notification Procedure
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing that a
proposed collection of information has been submitted to the Office of
Management and Budget (OMB) for review and clearance under the
Paperwork Reduction Act of 1995.
DATES: Fax written comments on the collection of information by July
22, 2019.
[[Page 29217]]
ADDRESSES: To ensure that comments on the information collection are
received, OMB recommends that written comments be faxed to the Office
of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer,
Fax: 202-395-7285, or emailed to [email protected]. All
comments should be identified with the OMB control number 0910-0342.
Also include the FDA docket number found in brackets in the heading of
this document.
FOR FURTHER INFORMATION CONTACT: Domini Bean, Office of Operations,
Food and Drug Administration, Three White Flint North, 10A-12M, 11601
Landsdown St., North Bethesda, MD 20852, 301-796-5733,
[email protected].
SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has
submitted the following proposed collection of information to OMB for
review and clearance.
Substances Generally Recognized as Safe (GRAS): Notification
Procedure--21 CFR Part 170, Subpart E and 21 CFR Part 570, Subpart E
OMB Control Number 0910-0342--Extension
The Federal Food, Drug, and Cosmetic Act (FD&C Act) requires that
all food additives (as defined by section 201(s) (21 U.S.C. 321(s)) be
approved by FDA before they are marketed. Section 409 of the FD&C Act
(21 U.S.C. 349) establishes a premarket approval requirement for ``food
additives.'' Section 201(s) of the FD&C Act provides an exclusion to
the definition of food additive and thus from the premarket approval
requirement, for uses of substances that are GRAS by qualified experts.
The GRAS provision of section 201(s) of the FD&C Act is implemented in
(part 170) 21 CFR part 170 and (part 570) 21 CFR part 570 for human
food and animal food, respectively. Part 170, subpart E and part 570,
subpart E provide a standard format for the submission of a notice.
This collection utilizes a voluntary administrative procedure for
notifying FDA about a conclusion that a substance is GRAS under the
conditions of its intended use in human food or animal food. The
information submitted to us in a GRAS notice is necessary to allow us
to administer efficiently the FD&C Act's various provisions that apply
to the use of substances added to food, specifically with regard to
whether a substance is GRAS under the conditions of its intended use or
is a food additive subject to premarket review. We use the information
collected through the GRAS notification procedures to complete our
evaluation within specific timelines.
Description of Respondents: The respondents to this collection of
information are manufacturers of substances used in human food and
animal food and feed.
In the Federal Register of March 12, 2019 (84 FR 8876), we
published a 60-day notice requesting public comment on the proposed
collection of information. No comments were received. We estimate the
burden of the information collection as follows:
Table 1--Estimated Annual Reporting Burden \1\
----------------------------------------------------------------------------------------------------------------
Number of
Activity; 21 CFR section Number of responses per Total annual Average burden Total hours
respondents respondent responses per response
----------------------------------------------------------------------------------------------------------------
GRAS notification procedure for 100 1 100 170 17,000
human food; 170.210-170.280
(part 170, subpart E)..........
GRAS notification procedure for 25 1 25 170 4,250
animal food and animal feed;
570.210-570.280 (part 570,
subpart E).....................
-------------------------------------------------------------------------------
Total....................... .............. .............. 75 .............. 21,250
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
Our estimated burden reflects an overall increase of 8,500 hours,
which corresponds to an increase in GRAS submissions for human food
from 50 to 100 we have received over the last 2 years.
Dated: June 17, 2019.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2019-13220 Filed 6-20-19; 8:45 am]
BILLING CODE 4164-01-P